1150617-52-9

Basic information

• Product Name: 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine
• Synonyms: 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine;5-BroMo-4-Methyl-7-azaindole ;1H-Pyrrolo[2,3-b]pyridine, 5-broMo-4-Methyl-;5-Bromo-4-methyl-7-zazindole
• CAS NO: 1150617-52-9
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.05858
• EINECS: 200-589-5
• Mol File: 1150617-52-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.654
• Storage Temp.: 2-8°C
• PKA: 13.28±0.40(Predicted)
• CAS DataBase Reference: 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine(1150617-52-9)
• EPA Substance Registry System: 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine(1150617-52-9)

Safety Data

• Hazardous Substances Data: 1150617-52-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine is a chemical compound with the molecular formula C9H8BrN3. It is a heterocyclic organic compound that contains both a pyrrole and a pyridine ring. 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine is commonly used in pharmaceutical research and development due to its potential as a building block for the synthesis of biologically active molecules. It is known for its ability to modify and control protein function, and it has been studied for its potential applications in the treatment of various diseases including cancer and neurological disorders. Additionally, it is used as a reagent in organic synthesis for the development of new drugs and other bioactive molecules.

Upstream product

• 1326216-30-1 5-bromo-4-methyl-3-((trimethylsilyl)ethynyl)pyridin-2-amine 
• 1150618-04-4 5-bromo-3-iodo-4-methyl-pyridin-2-ylamine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 

Relevant articles and documents

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.